SCHEMBL2746202

SCHEMBL2746202

CCc1c(C)cc(C(=O)NC(C(=O)O)c2ccccc2)c(=O)n1Cc1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 15/20 0.60
CNR1 P21554 13/20 0.60
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TP53 P04637 1/20 0.45
FAAH O00519 3/20 0.44
PPARG P37231 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5516384 1.00 CNR2 (0.60) CNR2CNR1MEN1KMT2ATP53
SCHEMBL5523764 0.93 CNR2 (0.56) CNR2CNR1MEN1KMT2ATP53
SCHEMBL27660212 0.93 CNR2 (0.56) CNR2CNR1MEN1KMT2ATP53
SCHEMBL5522248 0.90 CNR2 (0.50) CNR2CNR1MEN1KMT2ATP53
SCHEMBL2746633 0.90 CNR2 (0.50) CNR2CNR1MEN1KMT2ATP53
SCHEMBL11923131 0.89 CNR2 (0.48) CNR2CNR1MEN1KMT2ATP53
SCHEMBL5518289 0.88 CNR2 (0.61) CNR2CNR1MEN1KMT2ATP53
SCHEMBL2745876 0.88 CNR2 (0.61) CNR2CNR1MEN1KMT2ATP53
SCHEMBL2745542 0.86 CNR2 (0.56) CNR2CNR1TP53FAAHL3MBTL1
SCHEMBL5509529 0.86 CNR2 (0.66) CNR2CNR1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1993327-B 3-carbamoyl-2-pyridone derivatives SHIONOGI & CO 2013-02-06 CN disclosed
US-8367666-B2 3-carbamoyl-2-pyridone derivatives SHIONOGI & CO., LTD. (JP) 2013-02-05 US disclosed
US-20120208813-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVES SHIONOGI & CO., LTD. 2012-08-16 US disclosed
US-8178681-B2 methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency SHIONOGI & CO., LTD. (JP) 2012-05-15 US disclosed
US-20080103139-A1 3-Carbamoyl-2-Pyridone Derivative SHIONOGI & CO. LTD. (JP) 2008-05-01 US disclosed
EP-1806342-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2007-07-11 EP disclosed
CN-1993327-A 3-carbamoyl-2-pyridone derivatives SHIONOGI & CO (JP) 2007-07-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208813-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVES CNR2, CNR1, HRH4 CNR2 1/4885CNR1 2/4885MEN1 4298/4885
US-20080103139-A1 3-Carbamoyl-2-Pyridone Derivative CNR1, CNR2, HRH4 CNR2 2/4885CNR1 1/4885MEN1 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.